The state of hepatitis B

Global Epidemiology of viral hepatitis B

Dr 'Funmi Lesi Global Hepatitis Programme Global HIV, Hepatitis and STIs Programmes World Health Organization January 26, 2022





Outline

- 1. Background
- 2. Unmet critical need for prevention, treatment and care (2021 Progress Report)
- 3. Strategic shifts towards elimination in a new global health care era
- 4. Measuring progress and reaching hepatitis elimination
- 5. Key messages

Viral hepatitis B-a high burden disease



HBV is a small DNA virus that replicates through an RNA intermediate and can integrate into the host cell geneome. HBV CCCDNA is responsible for viral persistence




ή**Ň**à

a sint

The outcome of chronic infection is variable ranging from mild fibrosis to cirrhosis and decompensated liver disease and liver cancer.


Different routes of transmission in endemic and non-endemic communities.



Screening for chronic HBV is performed by testing for serum HBsAg. Testing for HBV DNA is routinely used in making treatment decisions and monitoring of disease course. Oral therapy (TDF, Entecavir) it is usually lifelong.

Burden of HBV infection (HBsAg) in the general population by WHO region, 2019:






World Health

¹Global Progress Report on HIV, viral hepatitis and sexually transmitted infection, 2021: <u>https://www.who.int/publications/i/item/9789240027077</u> ² WHO, Interim guidance for country validation of viral hepatitis elimination, 2021: <u>https://www.who.int/publications/i/item/9789240028395</u>

In highly endemic areas, transmission occurs primarily perinatally or in early childhood



In areas with intermediate endemicity, infection occurs in all age groups.

In areas of low hepatitis B seroprevalence, most infections occur in adults, especially among persons belonging to defined risk groups




17 Russia

20 Sudan

18 Thailand 19 Côte d'Ivoire

Increased estimated global burden from 257 million(2015) to 296 million (2019)




60m

Borid Health


Increased regional burden mostly in AFRO and SEARO accounting for global increase Decreased burden in Europe and the Americas


2021 Progress Report-unmet critical need for prevention, treatment and care



Status of the Global Hepatitis response

Impact targets by 2020 and 2030 and progress report (2021)







Source: International Agency for Research on Cancer and WHO, Global burden of cancer attributable to infections in 2018.


Progress report on HIV, viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies, 2016–2021: actions for impact. Geneva: World Health Organization; 2021

Significant Impact of hepatitis B vaccine on prevalence of HBsAg in children under 5 years



Before 2000: 4.7%






Despite the progress, 6.4 million chlidren aged < 5 with chronic HBsAg in 2019






Major gaps in testing and treatment towards public health elimination



Only 10% of estimated 296 million people with chronic HBV infection were diagnosed in 2019 with variation by regions (only 2% are on treatment)



Progress report on HIV, viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies, 2016–2021: actions for impact. Geneva: World Health Organization; 2021

Estimating the proportion of people with chronic hepatitis B 🍑 🕻 🌘 virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis

Mingjuan Tan*, Ajeet S Bhadoria*, Fugiang Cui, Alex Tan, Judith Van Holten, Philippa Easterbrook, Nathan Ford, Qin Han, Ying Lu, Marc Bulterys, Yvan Hutin

Findings Of the 13 497 studies, 162 were eligible and included in our analysis. These studies included 145 789 participants. The pooled estimate of the proportion of cirrhosis was 9% (95% CI 8-10), ranging from 6% (4-8) in community settings to 10% (9-11) in clinic settings. Examining the proportion of participants who had characteristics used to determine eligibility in the WHO guidelines, 1750 (10.1%) of 17394 had HBV DNA exceeding 20000 IU/mL, and 20425 (30.8%) of 66235 had ALT above the upper limit of normal. 32 studies reported eligibility for treatment according to WHO or any other guidelines, with a pooled estimate of eligibility at 19% (95% CI 18-20), ranging from 12% (6-18) for studies in community settings to 25% (19-30) in clinic settings.

Interpretation Many studies described people with HBV infection, but few reported information in a way that allowed assessment of eligibility for treatment. Although about one in ten of the 257 million people with HBV infection (26 million) might be in urgent need of treatment because of cirrhosis, a larger proportion (12-25%) is eligible for treatment in accordance with different guidelines. Future studies describing people with HBV infection should report on treatment eligibility, according to broadly agreed definitions.


26 million

People with HBV infection in need of urgent treatment because of cirrhosis





60a



Strategic shifts towards elimination in a new global health care era

Vision, goals and strategic directions (GHSS 2022-2030) World Health Organization



(Current draft)

A common vision	End epidemics and advance universal health coverage, primary health care and health security
Disease goals	End AIDS and the epidemics of viral hepatitis and sexually transmitted infections by 2030
Strategic directions	HIV Viral hepatitis Sexually transmitted strategy infections strategy
with shared and disease- specific actions	SD1. Deliver high-quality, evidence-based, people-centred, services SD2. Optimize systems, sectors and partnerships for impact SD3. Generate and use data to drive decisions for action SD4. Engage empowered communities and civil society SD5. Foster innovations for accelerated impact
Drivers of progress	 Gender, equity, and human rights Funding Leadership and partnerships

Eight Key shifts required to end the epidemic of viral hepatitis by 2030 (GHSS 2022-2030)

- 1. Greater public awareness of the importance of viral hepatitis B and C prevention, testing and treatment
- 2. Increased financial resources allocated
- 3. Scale-up of universal access to hepatitis B birth dose vaccine and improved services for prevention of vertical transmission
- 4. Continuous investment in primary prevention
- 5. Greatly increased access to hepatitis B and C virus testing and treatment
- 6. Simplified and decentralized service as well as integrated service delivery
- 7. Strengthened community and civil society
- 8. Innovations to accelerate action (incl HBV cure)



Measuring progress and reaching elimination

WHO Interim guidance for Validation of Viral hepatitis Elimination (2021) - implication for countries

Preduction reference targets (compared to 2015) 95% reduction 65% reduction 80% reduction 65% reduction HBV- and HCV-specific absolute prevalence, incidence and mortality targets -0.1% HBsAg prevalence, incidence and mortality arget: <2% MTCT rate (where use of targeted HepB-BD)* Annual mortality* (HBV) Annual incidence Annual (HCV) Programmatic targets ^d -0.1% HBsAg prevalence, incidence and mortality target: <2% MTCT rate (where use of targeted HepB-BD)* Annual mortality* (HBV) Annual mortality* (HBV) Programmatic targets ^d -0.1% HBsAg prevalence, incidence and mortality -0.1% HBsAg prevalence, incidence and mortality Annual mortality* (HBV) Sol (HCV) Programmatic targets ^d -0.1% HBsAg prevalence, incidence and mortality -0.1% HBsAg prevalence, incidence and mortality Annual mortality* (HBV) Sol (HCV) Programmatic targets ^d -0.1% HBsAg prevalence, incidence incidence -0.1% HBsAg prevalence, incidence incidence Annual mortality* (HBV) Sol (HCV) Sol (BD) -0.1% HBBAB vaccine coverage -0.1% HBBAB vaccine coverage -0.0% of people with HCV diagnosed with HBV and eligible for treatment are treated th -90% HepB3 vaccine coverage -9		Elimina	ation targets	Elimination of chronic HBV infection as a public health problem		Elimination of chronic HCV Infection as a public health problem	
 		reductio targets (on reference				Mortality 65% reduction
Options for validation of viral hepatitis elimination HBV vaccine birth dose (BD) ≥90% of people with HBV diagnosed ≥80% of people diagnosed with HBV and eligible for treatment are treated ^h ≥90% unsafe injections NBLE 2.2 Options for validation of viral hepatitis B BD (HepB-BD) coverage ^e B BD (HepB-BD) coverage ^e Prevention ≥90% HepB3 vaccine coverage ≥90% HepB3 vaccine coverage ≥90% HepB3 vaccine coverage ≥90% Unsafe injections 0% unsafe injections the PB HDV accine with target of this spills ad HeV, etHWHV Impact indicators with target of this spills ad HeV, etHWHV Mult HeV indicated ad infatt wondor coverage for networs at rints HeV back ad infatt wondor coverage of those infants at risk with targeted HepB-BD >90% coverage of maternal >90% coverage of maternal >90% coverage of maternal		absolute incidenc	e prevalence,	<0.1% HBsAg prevalence in ≤5 year olds ^{a,b} Additional target: <2% MTCT rate (where use of targeted		(HCV) ≤5/100 000	Annual mortality ^s (HCV) ≤2/100 000
(is part of tripe elimination dHW, syphilis and HBV, or HW/HBV/m MICT addr (dational target) in coarties with targeted within the great of members and infants infants at risk with targeted 0 B HOV as a public health problem Annual HOV incidence Coverage for members, resing and prophylasis coverage of maternal	Options for validation of viral hepatitis elimination BLE 2.2 Options for validation of elimination of viral hepatitis B and C as a public health problem ption Options for validation of elimination ption Options for validation of elimination ption Options for validation of elimination ption A HEW INTCT		HBV vaccine birth dose (BD) ≥90% HepB3 vaccine coverage ≥90% HepB timely hepatitis B BD (HepB-BD) coverage ^e Countries with targeted HBV vaccine birth dose (BD) ≥90% HepB3 vaccine coverage	 ≥90% of people with HBV diagnosed ≥80% of people diagnosed with HBV and eligible for treatment are treated^h Prevention ≥90% HepB3 vaccine coverage 	 ≥90% of people with HCV diagnosed ≥80% of people diagnosed with HCV are treated^g Prevention 0% unsafe injections 		
	(as part of triple elimination of HIV, MI syphilis and HBV, or HIV/HBV) ^a in	CT rate ^c (additional target) countries with targeted timely	vaccination coverage for newborns and infants HBV antenatal testing and antiviral	infants at risk with targeted HepB-BD			
		nual HCV incidence d HCV mortality	Coverage of prevention, testing and treatment	≥90% coverage of maternal antenatal HBsAg testing			
Option C (including HBV EMTCT) Annual HBV incidence (and MTCT rate) and HBV mortality Coverage of prevention, testing and treatment ≥90% coverage with antivirals for those eligible [#]	tion C HBV as a public health problem An (including HBV EMTCT) rat	nual HBV incidence (and MTCT e) and HBV mortality	treatment	≥90% coverage with			
Option D Elimination of both HBV and HCV as A B and C above A, B and C above A, B and C above A, B and C above HBV EMTCT)	a public health problem (including	B and C above					

ABSOLUTE targets: Enables direct comparison across puntries of progress towards imination) Avoids needs to establish baseline cidence or mortality

- Incidence should be in populations representative of the general or PWID population
- Programme coverage needs to be achieved and maintained for at least 2 years



WHO Guidelines for viral hepatitis is available to support hepatitis elimination

GLOBAL HEPATITIS REPORT.

2015

- **Elimination strategy**
- **HBV** Guidelines

2016

- **Revised HCV Guidelines (DAA)** \checkmark
- National plan development manual \checkmark 2017
- Baseline estimates: Global Hepatitis Report
- ✓ HBV/HCV testing Guidelines
- ✓ Injection safety campaign

2018

- ✓ Global hepatitis reporting system piloted
- ✓ HCV treatment Guidelines: Treat All
- Cost effectiveness calculators (HBV/HCV)

2019

✓ Consolidated strategic information guidelines (Feb 2019)

2020

VHBV PMTCT recommendations on antiviral medicine use in pregnancy 2021

✓ Interim Guidance for country validation of viral hepatitis elimination

✓ HCV self testing guidelines

√2022

✓ Update of Hepatitis B treatment guidelines & Consolidated VH guidelines NEW



Key messages

- Huge global HBV burden and significant regional variation
- Major gaps in treatment and care remain despite progress in the past 5 years
- We have the strategy and the tools to make hepatitis elimination a reality by 2030
- Building back better differently and enhancing opportunities from the COVID-19 response and embracing partnerships and innovations
- Political commitment and collective effort is needed to reach elimination by 2030

Acknowledgements



Colleagues-Global Hepatitis team Geneva, Regional and Country offices, Partners